Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct;61(10):2941-2957.
doi: 10.1111/trf.16612. Epub 2021 Aug 14.

Plasmavigilance-Adverse events among US Source plasma donors

Affiliations

Plasmavigilance-Adverse events among US Source plasma donors

George B Schreiber et al. Transfusion. 2021 Oct.

Abstract

Background: Source plasma (SP) is the primary starting material for 87% of plasma-derived medicinal products globally. Plasmavigilance is a program designed to collect, analyze, and monitor donor adverse events (AEs) across the SP collection industry. Donor retention depends on donors having a safe and satisfactory experience. This study analyzes AE rates and SP donor characteristics that may be predictors of an AE.

Study design and methods: Donation data for 1.1 million donors making 12,183,182 SP donations over a 4-month period were analyzed. This represented approximately 72% of the donations collected by the U.S. plasma industry. The Standard for Recording Donor Adverse Events was used for AE definitions and classifications.

Results: The overall AE rate was 15.85/104 donations. The two AEs with the highest rates were Hypotensive and Phlebotomy events (8.32 and 5.91/104 donations, respectively). Females had higher overall AE rates than males (25.76 vs. 9.85/104 donations), and first-time donors had higher overall AE rates than repeat donors (136.66 vs. 12.37/104 donations). Weight, body mass index, age, and pre-donation estimated blood volume also were predictors of AE.

Discussion: SP donors have low AE rates with 90% being events classified as Hypotensive or Phlebotomy. Special attention and mitigation strategies should be directed to donors who are young, lightweight (between 100 and 124 pounds), female, or first-time donors to further reduce the incidence of AE, continue to ensure the donor has a safe experience, and facilitate donor retention.

Keywords: adverse events; donation frequency; plasmavigilance; source plasma.

PubMed Disclaimer

Conflict of interest statement

GBS and MF are the employees of the Plasma Protein Therapeutics Association. MB is an employee of Biomat USA, Inc. JH and JL are the employees of Takeda/BioLife Plasma Services LP. GS is an employee of FEI Systems. And TS is an employee of CSL Plasma.

Figures

FIGURE 1
FIGURE 1
Donor adverse event rates (per 104 donations) by event category
FIGURE 2
FIGURE 2
Hypotensive and phlebotomy subcategory adverse event rates (per 104 donations)

Comment in

References

    1. Plasma Protein Therapeutics Association (2020). Current members. Plasma Protein Therapeutics Association. Available from: https://www.pptaglobal.org/about-us/current-members. Accessed Jul 13, 2020.
    1. Storch EK. Donor hemovigilance: a call to arms. Transfusion. 2020;60:1115–7. - PubMed
    1. Jones J, Sapiano M, Mowia S, et al. Has the trend of declining blood transfusions in the United States ended? Findings of the 2019 National Blood Collection and Utilization Survey. Transfusion. 2021. 10.1111/trf.16449. - DOI - PMC - PubMed
    1. Wiltbank T, Giordano G. The safety profile of automated collections: an analysis of more than one million collections. Transfusion. 2007;47:1002–5. - PubMed
    1. Winters J. Complications of donor apheresis. J Clin Apheresis. 2006;21:132–47. - PubMed